Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Fesoterodine BIC SR4 fasted, Fesoterodine BIC SR7 fasted, Fesoterodine BIC SR7 fed, Fesoterodine BIC SR4 fed (Treatment E in Part B), Fesoterodine BIC SR4 fed
Fesoterodine BIC SR4 · 1 trial · 1 indication
Area under the plasma concentration-time curve from time zero extrapolated to infinity.
Area under the plasma concentration-time curve from 0 to the time of the last quantifiable concentration.
Maximum Observed Plasma Concentration
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Sequence 1 (Part A) | OTHER | Treatment Sequence A,B,C and D |
| Cohort 1 Sequence 2 (Part A) | OTHER | Treatment Sequence B, A,C and D |
| Cohort 2 Sequence 1 (Part B) | OTHER | Treatment Sequence E, F, G, and H |
| Cohort 2 Sequence 2 (Part B) | OTHER | Treatment Sequence E, F, H and G |
| Cohort 2 Sequence 3 (Part B) | OTHER | Treatment Sequence F, E, G, and H |
| Cohort 2 Sequence 4 (Part B) | OTHER | Treatment sequence F, E, H, and G |
| Name | Type | Description |
|---|---|---|
| Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) | DRUG | 4 mg administered under fasted condition. |
| Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) | DRUG | 4 mg administered under fasted conditions. |
| Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) | DRUG | 4 mg administered under fed conditions. |
| Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) | DRUG | 4 mg sprinkled on apple sauce administered under fasting conditions |
| Fesoterodine BIC SR4 fed (Treatment E in Part B) | DRUG | 4 mg administered under fed conditions |
Inclusion Criteria 1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of signing the informed consent document (ICD). 2. Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and l...